Hydrazide derivatives as prostaglandin receptors modulators
View Patent ↗The present invention relates to hydrazide derivatives of Formula I notably for use as pharmaceutically active compounds, as well as to pharmaceutical formulations containing such hydrazide derivatives. Said hydrazide derivatives are useful in the treatment of preterm labor, dysmenorrhea, fertility disorders, asthma, hypertension, undesired blood clotting, preelampsia, eclampsia, an eosinophil disorder, undesired bone loss, renal dysfunction, an immune deficiency disorder, ichthyosis, elevated intraocular pressure, infertility, sexual dysfunction, gastric ulcers and inflammatory disorders.
1. A hydrazide derivative of Formula (I):
as well as its geometrical isomers, its optically active forms as enantiomers, diastereomers and mixtures of these, as well as salts thereof, wherein:
A is selected from the group consisting of C 3 -C 8 cycloalkyl, heterocycloalkyl, aryl and heteroaryl;
B is selected from the group consisting of C 1 -C 6 alkylene, C 2 -C 6 alkenylene, and C 2 -C 6 alkynylene;
R 1 is selected from the group consisting of H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, heterocycloalkyl, aryl C 1 -C 6 alkyl, heteroaryl C 1 -C 6 alkyl, aryl and heteroaryl;
R 2 and R 3 are independently selected from the group consisting of H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl and C 2 -C 6 alkynyl;
R 4 is selected from the group consisting of hydrogen and C 1 -C 6 alkyl;
R 5 is selected from the group consisting of hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 heteroalkyl, C 3 -C 8 cycloalkyl, C 3 -C 8 cycloalkyl C 1 -C 6 alkyl, aryl C 1 -C 6 alkyl, heteroaryl C 1 -C 6 alkyl, aryl and heteroaryl; and
n is an integer selected from the group consisting of 1, 2, 3, 4, 5 and 6.
2. The hydrazide derivative according to claim 1 , wherein A is selected from the group consisting of aryl and heteroaryl.
3. The hydrazide derivative according to claim 1 , wherein A is phenyl.
4. The hydrazide derivative according to claim 1 , wherein B is ethylene.
5. The hydrazide derivative according to claim 1 , wherein R 1 is C 1 -C 6 alkyl.
6. The hydrazide derivative according to claim 1 , wherein R 2 is H.
7. The hydrazide derivative according to claim 1 , wherein R 3 selected from the group consisting of H and methyl.
8. The hydrazide derivative according to claim 1 , Wherein R 3 is H.
9. The hydrazide derivative according to claim 1 , Wherein R 4 is H.
10. The hydrazide according to claim 1 , wherein n is 2.
11. The hydrazide derivative according to claim 1 , wherein A is phenyl; B is ethylenyl; R 1 is C 1 -C 6 alkyl; R 2 and R 4 are H; R 3 is selected from the group consisting of H and methyl; and n is 2.
12. The hydrazide derivative according to claim 1 , wherein R 5 is selected from the group consisting of H, C 1 -C 6 alkyl and C 3 -C 6 cycloalkyl.
13. The hydrazide derivative according to claim 1 , wherein R 5 is aryl C 1 -C 6 alkyl.
14. The hydrazide derivative according to claim 1 , wherein R 5 is heteroaryl C 1 -C 6 alkyl.
15. The hydrazide derivative according to claim 1 , wherein R 5 is C 3 -C 8 cycloalkyl.
16. The hydrazide derivative according to claim 1 , selected from the group consisting of: 4-(2-{1-acetyl-2-[4-(3-chlorophenyl)-3-hydroxybutyl]hydrazino}ethyl)benzoic acid;
4-(2-{1-acetyl-2-[3-hydroxy-4-(3-iodophenyl)butyl]hydrazino}ethyl)benzoic acid;
4-(2-{1-acetyl-2-[4-(3-bromophenyl)-3-hydroxybutyl]hydrazino}ethyl)benzoic acid;
4-(2-{1-acetyl-2-[4-(1,1′-biphenyl-3-yl)-3-hydroxybutyl]hydrazino}ethyl)benzoic acid;
4-[2-(1-acetyl-2-{3-hydroxy-4-[3-(phenylethynyl)phenyl]butyl}hydrazino)ethyl]benzoic acid;
4-{2-[1-acetyl-2-(3-hydroxy-4-phenylbutyl)hydrazino]ethyl}benzoic acid;
4-(2-{1-acetyl-2-[4-(4-chlorophenyl)-3-hydroxybutyl]hydrazino}ethyl)benzoic acid;
4-(2-{1-acetyl-2-[4-(4-fluorophenyl)-3-hydroxybutyl]hydrazino}ethyl)benzoic acid;
4-(2-{1-acetyl-2-[4-(3-ethynylphenyl)-3-hydroxybutyl]hydrazino}ethyl)benzoic acid;
4-(2-{1-acetyl-2-[4-(3-fluorophenyl)-3-hydroxybutyl]hydrazino}ethyl)benzoic acid;
4-[2-(1-acetyl-2-{3-hydroxy-4-[4-(phenylethynyl)phenyl]butyl}hydrazino)ethyl]benzoic acid;
4-{2-[1-acetyl-2-(3 -hydroxy-4-thien-2-ylbutyl)hydrazino]ethyl}benzoic acid;
4-[2-(1 -acetyl-2-{4-[3 -(cyclopropylethynyl)phenyl]-3-hydroxybutylhydrazino)ethyl]benzoic acid;
4-[2-(2-{3-hydroxy-4-[3 -(trifluoromethyl)phenyl]butyl}-1 -isobutyrylhydrazino)ethyl]benzoic acid;
4-[2-(2-{3-hydroxy-4-[3-(trifluoromethyl)phenyl]butyl}-1-propionylhydrazino)ethyl]benzoic acid;
4-[2-(1 -acetyl-2-{3-hydroxy-4-[3-(trifluoromethyl)phenyl]butyl}hydrazino)ethyl]benzoic acid;
4-{2-[1-acetyl-2-(3-cyclohexyl-3-hydroxypropyl)hydrazino]ethyl}benzoic acid; and a pharmaceutically acceptable salt of any of said compounds.
17. A hydrazide derivative selected from the group consisting of:
4-{2-[1-acetyl-2-(3-hydroxyoctyl)hydrazino]ethyl}benzoic acid;
4-{2-[1-acetyl-2-(3-hydroxyoctyl)-2-methylhydrazino]ethyl}benzoic acid;
4-{2-[1-acetyl-2-(3-hydroxybutyl)hydrazino]ethyl}benzoic acid; and a pharmaceutically acceptable salt of any of said compounds.
18. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and one or more compounds according to claim 1 .
19. A process for the preparation of a hydrazide derivative according to claim 1 , comprising the step of a reductive amination of a hydrazide of Formula II with a compound of Formula III in presence of a reducing agent:
wherein A, R 1 , R 2 , R 3 and n are as defined above; R 5 is —CH 2 —R 6 wherein R 6 is selected from C 1 -C 5 alkyl, C 2 -C 5 alkenyl, C 2 -C 5 alkynyl, C 1 -C 5 heteroalkyl, C 1 -C 5 alkyl C 1 -C 5 alkyl, aryl C 1 -C 5 alkyl and heteroaryl C 1 -C 5 alkyl.
20. A process for the preparation of a hydrazide derivative according to claim 1 , comprising the step of a reduction of a compound of Formula IV:
wherein A, B, R 1 , R 2 , R 3 , R 5 and n are as defined above.
21. The process according to claim 20 , further comprising the step of an addition of compound of Formula V to a compound of Formula II through a Michael addition [to obtain a compound of formula IV:]
wherein A, B, R 1 , R 2 , R 3 and R 5 are as defined above; R 4 is H.
22. The process according to claim 19 , further comprising the step of saponification of the resulting compound of Formula I, wherein R 1 is not H into a compound of Formula I, and wherein R 2 is H.
23. The process according to claim 19 , wherein A is phenyl.
24. A compound of Formula II:
as well as its geometrical isomers, its optically active forms as enantiomers, diastereomers and mixtures of these, as well as salts thereof, wherein A, R 1 , R 2 , R 3 and n are as defined above.
25. A compound of Formula IV:
as well as its geometrical isomers, its optically active forms as enantiomers, diastereomers and mixtures of these, as well as salts thereof, wherein A, R 1 , R 2 , R 3 , R 5 and n are as defined above.